Form 4: Editas Medicine CFO Sells Shares to Cover Tax Obligations from RSU Vesting

Editas Medicine's SVP and Chief Financial Officer, Amy Parison, sold 446 shares of common stock on June 3, 2025, at a weighted average price of $1.724 per share, to satisfy tax withholding obligations related to restricted stock unit vesting.

Summary

• Amy Parison, SVP, Chief Financial Officer of Editas Medicine, Inc. (EDIT), reported a sale of 446 shares of common stock.
• The transaction occurred on June 3, 2025, at a weighted average price of $1.724 per share, with prices ranging from $1.7239 to $1.7522.
• The sale was non-discretionary and executed pursuant to a Rule 10b5-1 automatic sales instruction plan adopted on July 7, 2022.
• The purpose of the sale was to meet tax withholding obligations arising from the vesting of restricted stock units (RSUs) on June 2, 2025.
• Following this transaction, Amy Parison beneficially owns 17,506 shares of Editas Medicine common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, non-discretionary transaction for tax purposes related to RSU vesting, which is a common occurrence for executives receiving equity compensation.

Positives

• The underlying event, the vesting of restricted stock units (RSUs), indicates that the executive is receiving compensation in the form of equity, aligning their interests with shareholders.

Negatives

• The sale of shares, while non-discretionary, reduces the direct equity ownership of a key executive.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022.
• The sale represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2025.
• The sale does not represent a discretionary trade by the Reporting Person.

Industry Context

This type of transaction, where executives sell shares to cover tax obligations upon the vesting of equity awards, is a common and routine practice across all industries, particularly in companies that utilize restricted stock units (RSUs) as a form of executive compensation.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary sale for tax purposes and not indicative of a change in management's confidence or a significant reduction in overall insider ownership.
• Employees: No direct impact beyond the reporting person.

Key Dates

Keywords

Editas Medicine, EDIT, Form 4, Insider Transaction, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Amy Parison, CFO, Rule 10b5-1 Plan